

Xtant Medical Holdings, Inc.  
Form 8-K  
September 09, 2015

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT PURSUANT**

**TO SECTION 13 OR 15(d) OF THE**

**SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): September 9, 2015

**Xtant Medical Holdings, Inc.**

(Exact Name of Registrant as Specified in Its Charter)

Delaware  
(State or Other Jurisdiction of Incorporation)

001-34951 (Commission File Number)	20-5313323 (IRS Employer Identification No.)
---------------------------------------	---

664 Cruiser Lane Belgrade, Montana (Address of Principal Executive Offices)	59714 (Zip Code)
---	---------------------

(406)  
388-0480  
(Registrant's  
Telephone  
Number,

Including  
Area Code)

(Former  
Name or  
Former  
Address,  
if  
Changed  
Since  
Last  
Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 7.01 Regulation FD Disclosure.**

The Company has issued a press release entitled “Xtant Medical Announces FDA Clearance of the Aranax™ Cervical Plate” which is attached as Exhibit 99.1 and incorporated herein.

The information in this Item 7.01 and the document attached as Exhibit 99.1 are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), nor otherwise subject to the liabilities of that section, nor incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

<b>Exhibit No</b>	<b>Description</b>
99.1	Press Release of Xtant Medical Holdings, Inc. dated September 9, 2015 entitled “Xtant Medical Announces FDA Clearance of the Aranax™ Cervical Plate”

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: September 9, 2015 **XTANT MEDICAL HOLDINGS, INC.**

By: /s/ Daniel Goldberger  
Name: Daniel Goldberger  
Title: Chief Executive Officer

**EXHIBIT INDEX**

- 99.1 Press Release of Xtant Medical Holdings, Inc. dated September 9, 2015 entitled “Xtant Medical Announces FDA Clearance of the Aranax™ Cervical Plate”